Cargando…
Identification of cytotoxic agents disrupting synovial sarcoma oncoprotein interactions by proximity ligation assay
Conventional cytotoxic therapies for synovial sarcoma provide limited benefit. Drugs specifically targeting the product of its driver translocation are currently unavailable, in part because the SS18-SSX oncoprotein functions via aberrant interactions within multiprotein complexes. Proximity ligatio...
Autores principales: | Laporte, Aimée N., Ji, Jennifer X., Ma, Limin, Nielsen, Torsten O., Brodin, Bertha A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085163/ https://www.ncbi.nlm.nih.gov/pubmed/27120803 http://dx.doi.org/10.18632/oncotarget.8882 |
Ejemplares similares
-
HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial Sarcoma
por: Laporte, Aimée N., et al.
Publicado: (2017) -
Intraosseous Synovial Sarcoma of the Proximal Tibia
por: Beck, Sarah E., et al.
Publicado: (2011) -
Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma
por: Raquib, Ainiah Rushdiana, et al.
Publicado: (2022) -
Downstream and Intermediate Interactions of Synovial Sarcoma-Associated Fusion Oncoproteins and Their Implication for Targeted Therapy
por: Przybyl, Joanna, et al.
Publicado: (2012) -
Tyrosine phosphorylation profiling via in situ proximity ligation assay
por: Elfineh, Lioudmila, et al.
Publicado: (2014)